<DOC>
	<DOCNO>NCT01334502</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth cancer cell block enzymes need cell growth . Monoclonal antibody , rituximab , block cancer cell different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , cyclophosphamide , doxorubicin hydrochloride , vincristine sulfate , prednisone , work different way stop growth cancer cell , either kill cell stop divide . Giving everolimus together rituximab , cyclophosphamide , doxorubicin hydrochloride , vincristine sulfate , prednisone may kill cancer cell . PURPOSE : This phase I trial study side effect best dose everolimus give together rituximab combination chemotherapy treat patient newly diagnose untreated diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>Everolimus , Rituximab , Combination Chemotherapy Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish maximum-tolerated dose ( MTD ) everolimus combination R-CHOP ( rituximab , cyclophosphamide , doxorubicin hydrochloride , vincristine sulfate prednisone ) chemotherapy . - To assess feasibility everolimus combination standard R-CHOP chemotherapy patient newly diagnose diffuse large B-cell lymphoma . Secondary - To describe toxicity associate everolimus combination R-CHOP chemotherapy . - To describe toxicity associate everolimus combination R-CHOP chemotherapy . - To assess rate event-free survival ( EFS ) 12 month diffuse large B-cell lymphoma patient treat everolimus combination R-CHOP chemotherapy . - To evaluate overall response rate , complete response rate , duration response , EFS , overall survival , progression-free survival patient treat everolimus combination R-CHOP chemotherapy . Tertiary - To profile gene expression use immunohistochemistry categorize patient germinal-center B-cell-like ( GBC ) v activate B-cell-like ( ABC ) v unclassified lymphoma subtype . ( exploratory ) - To determine whether previously identify predictive marker large cell lymphoma remain valid addition everolimus R-CHOP chemotherapy . ( exploratory ) OUTLINE : This multicenter , dose-escalation study everolimus follow feasability expanded-cohort study . Patients receive everolimus orally ( PO ) daily ( QD ) day 1-10 1-14 ; rituximab IV , cyclophosphamide IV , doxorubicin hydrochloride IV 15-60 minute , vincristine sulfate IV day 1 ; prednisone PO QD day 1-5 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Tumor biopsy collect laboratory study patient may undergo blood needle biopsy sample collection correlative study . After completion study treatment , patient follow every 3-6 month 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Untreated , histological diagnosis CD20positive diffuse large Bcell lymphoma Stage IIIV ( Ann Arbor Staging ) Measurable assessable disease define least one following : A lymph node tumor mass ≥ 2.0 cm least one dimension CT portion PET/CT scan , CT scan , MRI Diffuse infiltration organ stomach , bone marrow , peripheral blood , liver , lung , bowel lymphoma without discrete mass would constitute assessable , measurable , disease Diagnostic tissue slide paraffinembedded block must available No CNS lymphoma cerebrospinal fluid involvement malignant lymphoma cell PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ( ANC ) ≥ 1,500/mm³ Peripheral platelet count ≥ 100,000/mm³ Hemoglobin ( HgB ) &gt; 9.0 g/dL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) For total bilirubin &gt; 1.5 time ULN , direct bilirubin must normal Alkaline phosphatase ≤ 3 time ULN ( ≤ 5 time ULN evidence direct liver involvement lymphoma ) AST ≤ 3 time ULN ( ≤ 5 time ULN evidence direct liver involvement lymphoma ) Creatinine ≤ ULN Negative serum urine pregnancy test Not pregnant nurse Men woman childbearing potential must willing employ adequate contraception throughout study for12 month last dose study drug Willing return National Central Cancer Treatment Group ( NCCTG ) enrol institution followup Willing provide archival tissue primary diagnosis ( original lymphoma lymph node tissue biopsy ) Willing abstain eating grapefruit drinking grapefruit juice duration study Diabetic patient take insulin oral antidiabetic therapy must HbA1c ≤ 8 % , fast serum glucose ≤ 110 % ULN HIVpositive patient must CD4 count ≥ 400/mm³ No comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimens No immunocompromised patient ( relate use corticosteroid ) include patient know HIV positive CD4 count &lt; 400/mm³ No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Severely impaired lung function Uncontrolled diabetes define fast serum glucose &gt; 1.5 time ULN Optimal glycemic control achieve start trial therapy Psychiatric illness/social situation would limit compliance study requirement Liver disease cirrhosis severe hepatic impairment Chronic active hepatitis Chronic persistent hepatitis history hepatitis B C No active malignancy except nonmelanotic skin cancer carcinoma situ cervix If history prior malignancy , patient must receive specific treatment ( hormonal therapy ) cancer No positive hepatitis B antigen ( HBsAg ) hepatitis C serology ( HCV ) test meet follow criterion : Hepatitis B surface antigen ( HbsAg ) antibody hepatitis B core ( antiHBc ) hepatitis C antibody All patient must screen prior registration Patients evidence chronic acute infection either hepatitis B C may treat protocol PRIOR CONCURRENT THERAPY : Not receive investigational agent would consider treatment primary neoplasm No plan immunization attenuate live vaccine ≤ 7 day prior registration study period Close contact receive attenuated live vaccine avoid treatment everolimus Examples live vaccine include intranasal influenza , measles , mumps , rubella , oral polio , BCG , yellow fever , varicella , TY21a typhoid vaccine Not currently enzymeinducing anticonvulsant strong inducer CYP3A4 ( efavirenz , nevirapine , barbiturate , carbamazepine , modafinil , phenobarbital , phenytoin , rifabutin , rifampin , pioglitazone , St. John wort ) strong inhibitor CYP3A4 ( indinavir , nelfinavir , ritonavir , clarithromycin , itraconazole , voriconazole , ketoconazole , nefazodone , saquinavir , telithromycin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>